Thyroid hormones (TH) enhance cardiac function and reverse gene changes typical of pathologic hypertrophy. However, reports in humans, but not animals, indicate that excess TH can cause heart failure (HF). Also, the effects of TH on normal and cardiomyopathic hearts is likely to be different. The goal of this study was to characterize the effects of prolonged hyperthyroidism on cardiac function, chamber and cellular remodeling, and protein expression in both normal and cardiomyopathic hearts. Hyperthyroidism was induced in 3 mo old normal BIO F1B and dilated cardiomyopathic BIO TO2 hamsters. After TH treatment for 10 days and 2 months, hemodynamics, echos, myocyte length, histology, and protein expression were assessed.
Introduction
Thyroid hormone (TH) has profound effects on the cardiovascular system including tachycardia, hypertrophy, and enhanced function (2, 16) . TH stimulates myocyte hypertrophy, which is often associated with enhanced function. The mechanism behind this effect of TH is unknown but many studies have implicated changes in expression of myosin heavy chain (MHC) isoforms and Ca2+ handling proteins (3, 12, 15) . Though enhanced cardiac function is the most recognized outcome of hyperthyroidism, dysfunction has also been reported. Case studies have described patients with dilated cardiomyopathy in which hyperthyroidism is the primary cause(13, 14, 20, 26, 32, 34) . Interestingly, restoring normal levels of TH often reverses the dilatation and dysfunction, making hyperthyroid cardiomyopathy a potentially curable form of heart failure. To our knowledge, there have not been any animal studies showing that hyperthyroidism can result in overt heart failure. A recent study suggested that after 1 month of thyroid hormone treatment cardiac function begins to decline (7) . However, ejection fraction in the thyroid treated group was still higher than the sham group. Since many of the studies suggesting TH-related dilated cardiomyopathy have been patient case studies, the underlying pathophysiologic mechanisms of TH induced heart failure are poorly understood.
BIO TO-2 hamsters develop a dilated cardiomyopathy due to a mutation in sarcoglycan. These hamsters have altered microcirculation causing ischemia which results in myocyte loss and replacement fibrosis (24, 29) . Since TH can stimulate angiogenesis and cause vasodilation (5, 25) , the impaired coronary circulation might be improved with TH treatment which could potentially reduce myocyte loss and replacement fibrosis. In addition, TH repress collagen expression in the heart, which could reduce extracellular matrix remodeling compared to controls (4, 33) . Therefore, the effects of TH may be distinctly different in a cardiomyopathic 4 model compared to controls. Of additional importance in selection of this model, we have recently found that BIO-TO-2 hamsters develop sub-clinical hypothyroidism (e.g. normal T3 but elevated TSH) (8) .
The goal of this study was to characterize the effects of prolonged hyperthyroidism on cardiac function, chamber and cellular remodeling, and protein expression in both a control and cardiomyopathic animal model. Because TH has such a wide variety of effects on cardiac tissue, the remodeling pattern due to hyperthyroidism in these two animal strains is likely to be different.
Materials and Methods

Experimental Design
BIO TO-2 hamsters, an animal model of dilated cardiomyopathy due to a mutation in sarcoglycan, develop progressive chamber dilation, myocardial fibronecrosis, and death by about 10 months of age (27) . Three month old male BIO F1B (controls) and BIO TO-2 hamsters were obtained from Bio Breeders Inc (Watertown, MA). Based on mean body weight, F1B and TO2 hamsters were randomized into treated and untreated groups. Animals in treated group were fed pellets containing 0.1% Grade I desiccated thyroid hormone (Sigma #T1251). The pellets containing TH were made by Bio-Serv, Inc. (Frenchtown, NJ). After 10 days of treatment, 10 hamsters from each group were sacrificed to determine the short term effects of thyroid hormone treatment. Additional hamsters were sacrificed after 2 months of treatment to determine the long term effects. At the end of the treatment period, echo and hemodynamic data were collected and hearts were removed. Myocytes were isolated from 7 animals in each group. In the remaining animals, hearts were sectioned transversely and slices were snap frozen or immersion fixed in 10% formalin for histological analysis. Isolated cell aliquots were fixed in glutaraldehyde (myocyte length measurements, 40 cells per heart) and snap frozen (protein analysis).
Echocardiography
Echocardiography was performed in animals just prior to being killed. Animals were anesthetized with 1.5% isofluorane. The chest was shaved, and the animals were placed on a warming pad to maintain normal body temperature. Echocardiographic gel was applied to the left hemithorax. Echos were performed using a HP Sonos 2000 (7.5MHz transducer). The transducer was lightly placed on the left hemithorax and two-dimensionally targeted M-mode echocardiograms were obtained from short-axis views of the left ventricle at the level of the 6 papillary muscle tips. M-mode tracings were used to measure left ventricular dimensions in systole and diastole along with ejection fraction (EF).
Hemodynamics and Mechanics
To obtain hemodynamic measurements, a Millar ultraminiature pressure transducer catheter (model SPR-835, 1.4F, Houston, Texas) was fed through the right carotid artery into the left ventricle. Data were collected and processed electronically using a Digi-Med Heart Performance Analyzer (Micro-Med, Louisville, KY). The following data were collected: heart rate, Peak systolic pressure, and +/-dP/dT.
Western blot
Frozen whole left ventricular tissue was powdered in liquid nitrogen and RIPA buffer with protease cocktail inhibitor (EMD Biosciences Inc., San Diego, CA), 1mM PMSF, and 1mM sodium orthovanadate. Each sample was incubated at 4°C for 15 minutes and sonicated to completely homogenize the tissue. Cell lysates were centrifuged at 14,000 RPM for 15 minutes.
The supernatant was collected, aliquoted and stored at -80°C until time of use. Protein concentrations of cell lysates were determined by a BCA protein assay. Samples were then mixed with Laemelli buffer containing 5% -mercaptoethanol and 10µg of protein was loaded onto SDS-PAGE gels. Protein was transferred to PVDF membranes and detected by antibodies specific to SERCA2a (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA) and / -MHC.
Hybridomas producing antibodies specific to MHC (BA-G5 hybridoma; ATCC) and MHC (A4.951 hybridoma; ATCC) from American Type Culture Collection (ATCC; Manassas, VA) were cultured and the medium was collected and used for Western blotting. Resultant bands were detected through chemiluminescence (Pierce, Rockford, IL) and quantified using a Versadoc Imaging System model 3000 (Biorad Laboratories, Inc., Hercules, CA).
Histology
Formalin-fixed transverse sections were, frozen, cryo-sectioned at 5 µm, and stained with hematoxylin and eosin were examined in the 2 month treatment group. Because of calcifications in TO2 hamsters, frozen sections with more uniform hardness provided better quality sections than paraffin blocks. The percentages of viable ventricular myocytes and areas of fibronecrotic replacement were determined morphometrically by point counting morphometry as described previously(9, 10). Histological sections were viewed under a microscope with a color video camera, and data were collected from 10 randomly selected fields from each animal.
T3 Assay
Blood samples were separated into serum aliquots and frozen. T3 levels were measured using a solid phases competitive ELISA kit from Bio-Quant (San Diego, CA) according to the manufacturers protocol.
Statistics
All data are expressed as means with standard deviation. Two-tailed unpaired t-tests were used to determine whether there were significant differences between treated or untreated groups. No comparisons were made between the F1B and TO2 models.
Results
Physical Parameters
TH treatment for 10 days did not affect body weight (BW), but significantly increased heart weight (HW) and heart weight/body weight (HW/BW; Table 1 ). After 2 months of treatment, BW was not significantly changed in either group with treatment. There was, however, a tendency for an increase in BW in the treated groups. This effect has been previously reported in cardiomyopathic hamsters (28) . HW and HW/BW were both significantly increased with long-term TH. Also, levels of T3 were significantly increased in both animal models with treatment (figure 1).
Echocardiography
TH treatment for 10 days had no significant effects on echo parameters in either hamster strain (figure 2). After 2 months, there was a dramatic effect on chamber remodeling in F1B-Tx.
There were significant increases in LVID in both systole and diastole. Ejection fraction was also significantly reduced in F1B-Tx. Thus, echo data indicated that hyperthyroidism causes cardiac dilatation and dysfunction in control hamsters. Interestingly, there were no differences in chamber dimensions or ejection fraction between TO2-Untx and TO2-Tx.
Hemodynamics
After 10 days of treatment, heart rate was significantly increased in both F1B-Tx and TO2-Tx (figure 3). +dP/dT increased in TO2-Tx and tended to increase in F1B-Tx (not significant). There was also a strong tendency for increased LVPes in TO2-Tx. These results show that short-term treatment caused tachycardia and tended to enhance function. After 2 months of treatment, heart rate was not different from untreated animals. F1B-Tx had 9 significantly reduced +/-dP/dT vs F1B-Untx but there were no changes in these parameters in TO2-Tx vs TO2-Untx.
Cell Shape and Histology
After 10 days treatment, there were no significant changes in myocyte length in F1B-Tx or TO2-Tx (figure 4). However, 2 months treatment with TH induced cell lengthening in both F1B-Tx and TO2-Tx. The percentage of fibronecrosis was examined in the 2 month treatment groups. Areas of fibrosis or necrosis were not found in any F1B hamsters. Fibronecrosis was extensive in TO2-Untx compared to F1B-Untx. The amount of fibrosis and necrosis was significantly reduced in TO2-Tx compared to TO2-Untx after 2 months of treatment.
Western blot analysis
After 2 months, TH had typical effects on the expression of genes important for normal cardiac function including -MHC, -MHC, and SERCA. Figure 5 shows that TH increased protein expression of -MHC in F1B-Tx. -MHC expression was reduced in both F1B-Tx and TO2-Tx. SERCA2a was increased in TO2-Tx.
Discussion
There were three key findings in this study. First, it was shown that hyperthyroidism can cause cardiac dilatation and ventricular dysfunction in normal animals. Typical of heart failure, chamber dilatation in these animals was associated with excessive myocyte lengthening.
Secondly, even with onset of chamber dysfunction, F1B-Tx animals displayed a genetic phenotype normally associated with improved function ( , MHC isoforms). This suggests that reversal of MHC expression, believed to be beneficial, does not always translate into improved cardiac function. Lastly, unlike the situation with normal animals, hyperthyroidism induced in cardiomyopathic animals did not accelerate progression of chamber dilatation or dysfunction. At the cellular level, however, it appears that the potential detrimental effect of accelerated myocyte lengthening was countered by reduced fibronecrosis.
F1B-Tx had increased internal dimensions and chamber dysfunction (evident by reduced
EF and +/-dP/dT). These results are similar to those reported in case studies from patients with Grave's disease (1, 11) . Increased myocyte length, without evidence of fibronecrosis, was the key cellular change leading to chamber dilatation in F1B-Tx hamsters. Interestingly, despite the onset of systolic pump dysfunction in F1B-Tx hamsters, MHC isoforms shifted to a more energetic profile (e.g. increased -MHC and reduced -MHC). Though TH is known to increase expression of -MHC and reduce expression of -MHC, heart failure is associated with the converse. Since the myosin isoform switch is believed to play a key role in chamber function, it might be predicted that TH would increase MHC and decrease MHC during the early period where cardiac function is increased, but eventually this change would be reversed as cardiac dysfunction ensued. In many studies, reversal of the fetal pattern of MHC expression has been used as a marker for improved cardiac function (17, 18) and it has been suggested that MHC isoform changes contribute to disease progression in human DCM (19 (6, 30). In the current studies, we believe that TH prevented myocyte loss and development of ischemic lesions. It is likely that early lesions of this type in untreated TO-2 hamsters may contribute to chamber dilatation as they become very pliant and extended before being stiffened by collagen deposition. However, further work is needed to confirm this hypothesis.
Thyroid-induced tachycardia is one of the most widely used clinical parameters for identification of hyperthyroidism. In this study, 10 days of TH caused a significant increase in heart rate. After 2 months of TH, however, heart rate was not different between treated and untreated hamsters of either strain. These data suggest that heart rate is increased in the early stages of hyperthyroidism, but at later stages may decline into the normal range with progression to failure. Therefore, heart rate may not always be a good predictor of hyperthyroidism when the disease has been present for prolonged periods of time. In fact, our results raise the possibility that it may be easy to overlook hyperthyroidism as a cause of heart failure in this situation.
Though this may occur in very few cases, clinicians should be aware of the possibility since this type of heart failure may be easily cured with anti-thyroid treatment.
There is a need for better inotropic drugs to treat severe HF. TH is well known for its inotropic effect and could potentially be used in heart failure patients. However, care must be taken to prevent overdosing which would lead to undesirable side-effects. Interestingly, this study suggests that induced hyperthyroidism (e.g. overdose) resulted in greater adverse effects on ventricular remodeling and function in normal animals than in cardiomyopathic hamsters.
Though the exact reason for this is not completely clear, it may be related to the presence of thyroid dysfunction in TO2 hamsters. Also, TH treatment of TO2 hamsters exerted a beneficial effect on myocardial fibronecrosis, a condition that was not present in normal animals.
Therefore, a potential treatment strategy might be to retain the beneficial effects of TH without the undesirable side-effects. The thyroid hormone analog, DITPA, may be a safer alternative since it appears to promote increased inotropy with reduced risk of tachycardia (22, 23) . Clinical trials in VA heart failure patients are currently being conducted with DITPA. While preliminary studies in humans treated with DITPA appear promising (21), many important questions remain about the potential effects of thyroid hormones and analogs in treatment of heart failure.
Limitation of the study. While excessive TH treatment of TO2 hamsters did not appear to adversely affect chamber remodeling and function, 6 TO2-Tx hamsters died during the final week of the study while only 2 F1B-Tx hamsters died. This suggests an increase in mortality in the TO2-Tx group. However, most of the deaths occurred during or shortly after transportation from the animal facility to our lab. Additionally, a renovation project was initiated on the building housing the animals just prior to this time so increased stress may also have been a contributing factor. Indeed, hyperthyroidism is known to produce stress in the absence of other mitigating circumstances. While we do not know if there were any important differences in the TO2-Tx and F1B-Tx animals that died during the final week of the study, we believe data 13 presented here provide a reliable understanding of the effects of excessive TH in these animals.
Nonetheless, we also felt it was important to disclose this information. 
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